Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapy

被引:6
作者
Chan, Wei Yen [1 ,2 ]
Lee, Jenny H. [1 ,3 ]
Stewart, Ashleigh [1 ,2 ]
Diefenbach, Russell J. [1 ,2 ]
Gonzalez, Maria [2 ]
Menzies, Alexander M. [2 ,4 ,5 ]
Blank, Christian [6 ,7 ,8 ]
Scolyer, Richard A. [2 ,4 ,9 ,10 ,11 ]
Long, Georgina V. [2 ,4 ,5 ,9 ]
Rizos, Helen [1 ,2 ]
机构
[1] Macquarie Univ, Fac Med Hlth & Human Sci, Sydney, NSW, Australia
[2] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia
[3] Chris Obrien Lifehouse, Dept Med Oncol, Sydney, NSW, Australia
[4] Univ Sydney, Fac Med & Hlth, Sydney, NSW, Australia
[5] Royal North Shore & Mater Hosp, Dept Med Oncol, Sydney, NSW, Australia
[6] Netherlands Canc Inst NKI, Dept Med Oncol, Amsterdam, Netherlands
[7] Leiden Univ, Med Ctr LUMC, Dept Med Oncol, Leiden, Netherlands
[8] Univ Clin Regensburg UKR, Dept Hematol & Med Oncol, Regensburg, Germany
[9] Univ Sydney, Charles Perkins Ctr, Sydney, NSW, Australia
[10] Royal Prince Alfred Hosp, Tissue Pathol & Diagnost Oncol, Sydney, NSW, Australia
[11] NSW Hlth Pathol, Sydney, NSW, Australia
基金
英国医学研究理事会;
关键词
Circulating tumour DNA; Stage III melanoma; Neoadjuvant therapy; Recurrence risk; SURVIVAL; ADJUVANT; IPILIMUMAB;
D O I
10.1186/s13046-024-03153-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundNeoadjuvant therapy improves recurrence-free survival (RFS) in resectable stage III cutaneous melanoma. However, accurately predicting individual recurrence risk remains a significant challenge. We investigated circulating tumour DNA (ctDNA) as a biomarker for recurrence in measurable stage IIIB/C melanoma patients undergoing neoadjuvant immunotherapy. MethodsPlasma samples were collected pre-neoadjuvant treatment, pre-surgery and/or six weeks post-surgery from 40 patients enrolled in the OpACIN-neo and PRADO clinical trials. Patients received two cycles of ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) before surgery. Cell free DNA (cfDNA) underwent unbiased pre-amplification followed by tumour-informed mutation detection using droplet digital polymerase chain reaction (ddPCR) with the Bio-Rad QX600 PCR system. ResultsPre-treatment ctDNA was detectable in 19/40 (48%) patients. Among these, 17/19 (89%) zero-converted within six weeks of surgery and none recurred. Positive ctDNA post-surgery (N = 4), irrespective of pre-treatment ctDNA status, was 100% predictive of recurrence (sensitivity 44%, specificity 100%). Furthermore, ctDNA cleared prior to surgery in 7/9 (78%) patients who did not recur, warranting further investigation into ctDNA-guided surgical management. ConclusionPost-surgery ctDNA positivity and zero-conversion are highly predictive of recurrence, offering a window for personalised modification of adjuvant therapy.
引用
收藏
页数:9
相关论文
共 50 条
[21]   Circulating Tumor DNA in High-Risk Stage II/III Cutaneous Melanoma: A Feasibility Study [J].
Rhodin, Kristen E. ;
O'Connor, Margaret H. ;
Therien, Aaron ;
Hollander, Shayna ;
Geron, Viviana ;
Nair, Uma ;
Rakestraw, Emily ;
Salama, April K. ;
Shah, Riddhishkumar ;
Tyler, Douglas S. ;
Beasley, Georgia M. .
ANNALS OF SURGICAL ONCOLOGY, 2025, 32 (07) :5292-5299
[22]   Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry [J].
Ozkan, A. ;
Kapiteijn, E. ;
van den Bos, F. ;
Aarts, M. J. B. ;
van den Berkmortel, F. W. P. J. ;
Blank, C. U. ;
Bloem, M. ;
Blokx, W. A. M. ;
Boers-Sonderen, M. J. ;
Bonenkamp, J. J. ;
van den Eertwegh, A. J. M. ;
de Groot, J. W. B. ;
Haanen, J. B. ;
Holtslag, C. E. ;
Hospers, G. A. P. ;
Piersma, D. ;
van Rijn, R. S. ;
Boer, A. M. Stevense-den ;
Suijkerbuijk, K. P. M. ;
van der Veldt, A. A. M. ;
Vreugdenhil, G. ;
Wouters, M. W. J. M. ;
Portielje, J. E. A. ;
de Glas, N. A. .
EUROPEAN JOURNAL OF CANCER, 2024, 212
[23]   Presence of Circulating Tumor Cells Predates Imaging Detection of Relapse in Patients with Stage III Melanoma [J].
Lucci, Anthony ;
Addanki, Sridevi ;
Chiang, Yi-Ju ;
Meas, Salyna ;
Sarli, Vanessa N. N. ;
Upshaw, Joshua R. R. ;
Manchem, Mayank ;
Patel, Sapna P. P. ;
Wargo, Jennifer A. A. ;
Gershenwald, Jeffrey E. E. ;
Ross, Merrick I. I. .
CANCERS, 2023, 15 (14)
[24]   Trends and outcomes for patients receiving neoadjuvant therapy for stage I to III gastric gastrointestinal stromal tumors [J].
Bennett, Cade F. ;
Janczewski, Lauren M. ;
Vitello, Dominic ;
Wells, Amy ;
Obeidin, Farres ;
Alexiev, Borislav A. ;
Hayes, John ;
Faruqi, Fahad ;
Bentrem, David ;
Wayne, Jeffrey D. ;
Abad, John ;
Hardy, Ashley ;
de Viverios, Pedro Hermida ;
Pollack, Seth M. ;
Chawla, Akhil .
JOURNAL OF GASTROINTESTINAL SURGERY, 2025, 29 (08)
[25]   Quality of life and mental health in real-world patients with resected stage III/IV melanoma receiving adjuvant immunotherapy [J].
Pedersen, Sidsel ;
Holmstroem, Rikke B. B. ;
von Heymann, Annika ;
Tolstrup, Laerke K. K. ;
Madsen, Kasper ;
Petersen, Morten Aagaard ;
Haslund, Charlotte A. A. ;
Ruhlmann, Christina H. H. ;
Schmidt, Henrik ;
Johansen, Christoffer ;
Svane, Inge Marie ;
Ellebaek, Eva .
ACTA ONCOLOGICA, 2023, 62 (01) :62-69
[26]   Not Waiting to Progress; How the COVID-19 Pandemic Nudged Neoadjuvant Therapy for Stage III Locally Advanced Melanoma Patients [J].
Kinaschuk, Katie ;
Cheng, Tina ;
Brenn, Thomas ;
McKinnon, J. Gregory ;
Temple-Oberle, Claire .
CURRENT ONCOLOGY, 2023, 30 (05) :4402-4411
[27]   Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma [J].
Sharon, C. E. ;
Tortorello, G. N. ;
Ma, K. L. ;
Huang, A. C. ;
Xu, X. ;
Giles, L. R. ;
Mcgettigan, S. ;
Kreider, K. ;
Schuchter, L. M. ;
Mathew, A. J. ;
Amaravadi, R. K. ;
Gimotty, P. A. ;
Miura, J. T. ;
Karakousis, G. C. ;
Mitchell, T. C. .
ANNALS OF ONCOLOGY, 2023, 34 (09) :806-812
[28]   Prospective Molecular Profiling of Circulating Tumor Cells from Patients with Melanoma Receiving Combinatorial Immunotherapy [J].
Lin, Selena Y. ;
Chang, Shu-Ching ;
Lam, Stella ;
Ramos, Romela Irene ;
Tran, Kevin ;
Ohe, Shuichi ;
Salomon, Matthew P. ;
Bhagat, Ali Asgar S. ;
Lim, Chwee Teck ;
Fischer, Trevan D. ;
Foshag, Leland J. ;
Boley, Christine L. ;
O'Day, Steven J. ;
Hoon, Dave S. B. .
CLINICAL CHEMISTRY, 2020, 66 (01) :169-177
[29]   Early Recurrence in Sentinel Lymph Node Positive Stage III Melanoma Patients [J].
Baker, Justin J. ;
Ollila, David W. ;
Deal, Allison M. ;
Frank, Jill ;
Amos, Keith D. ;
Meyers, Michael O. .
AMERICAN SURGEON, 2012, 78 (07) :808-813
[30]   Higher proportions of CD39+tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy [J].
Attrill, Grace Heloise ;
Owen, Carina N. ;
Ahmed, Tasnia ;
Vergara, Ismael A. ;
Colebatch, Andrew J. ;
Conway, Jordan W. ;
Nahar, Kazi J. ;
Thompson, John F. ;
da Silva, Ines Pires ;
Carlino, Matteo S. ;
Menzies, Alexander M. ;
Lo, Serigne ;
Palendira, Umaimainthan ;
Scolyer, Richard A. ;
Long, Georgina, V ;
Wilmott, James S. .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (06)